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Abstract
Gastrointestinal stromal tumors (GISTs) are potentially malignant mesenchymal tumors that can give rise to distant
metastases, mainly in the liver. The co-occurrence of synchronous primary liver tumors (e.g., hepatocellular
carcinoma (HCC)) in patients with GIST is extremely rare. This report describes a 77-year-old male patient with liver
metastasis of GIST originating in the small intestine and synchronous HCC. The patient had undergone resection of
the small intestine for the primary GIST 3 years earlier and partial hepatectomy and radiofrequency ablation for liver
metastases of GIST 1 year earlier. Despite the continuation of adjuvant therapy with imatinib, two new lesions in
the liver were detected by follow-up computed tomography scanning, which showed the gradual enlargement of
one tumor. A second hepatectomy was performed. Pathological examination revealed that one tumor was a liver
metastasis of GIST and the other was a primary HCC. To our knowledge, this is the first report of the synchronous
co-occurrence of a liver metastasis of GIST and a primary HCC.
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Background
Gastrointestinal stromal tumors (GISTs) are rare mesen-
chymal tumors of the gastrointestinal tract, arising
mainly in the stomach and small intestine. GISTs were
identified as tumors of the interstitial cells of Cajal, or
their precursors, with more than 75 % showing muta-
tions in KIT, thus defining a specific sarcoma subtype
[1]. The availability of antibodies to KIT (CD117) has
made the diagnosis easier [2]. Distant metastases of
GIST arise predominantly in the liver and peritoneum,
but rarely in the lymph nodes, bones, lungs, and other
sites [3, 4]. Although GISTs have been reported to occur
together with other malignancies, including chronic
lymphocytic leukemia, lymphoma, renal cell carcinoma,
and gastric cancer [5], few reports have described the
synchronous occurrence of primary GISTs and hepato-
cellular carcinoma (HCC). To our knowledge, there have
been no reports to date of the co-occurrence of a liver
metastasis of GIST and primary HCC in the liver of
individual patients.
Case presentation
Three years ago, a 77-year-old male patient was admit-
ted to our hospital with mild upper abdominal pain and
mild nausea. Small intestinal fiber and computed tomog-
raphy (CT) scanning showed a tumor in the small intes-
tine and two tumors in the liver, a 22 × 11 mm nodular
lesion in segment 3 and a 15 × 10 mm nodular lesion in
segment 7. An endoscopic biopsy was obtained from the
tumor in the small intestine, with pathological results
compatible with GIST (KIT+; vimentin+). Imaging find-
ings of the two liver tumors were consistent with metas-
tases of GIST, and he was diagnosed with GIST
originating in the small intestine and liver metastases of
GIST. Because he had abdominal symptoms, he first
underwent resection of the small intestine for the pri-
mary lesion. KIT mutation analysis of the resected
tumor specimen showed an in-frame deletion of a por-
tion of the juxtamembrane domain (exon 11). He was
subsequently started on treatment with imatinib for the
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metastatic lesions. However, he experienced skin erup-
tions, a side effect of imatinib treatment. Eight months
after resection of the small intestine, he underwent par-
tial hepatectomy for the tumor in segment 3 and radio-
frequency ablation (RFA) for the tumor in segment 7. A
follow-up CT scan 5 months later showed tumor recur-
rence in segment 4 of the liver. He was again started on
treatment with low-dose imatinib, during which the
metastatic lesion became gradually enlarged, although
the internal CT image showed a cystic change. In
addition, a new lesion with arterial enhancement was de-
tected in segment 8 of the liver. CT findings of these
two tumors differed markedly, in that the S8 tumor
showed enhancement in the arterial phase, while the S4
tumor did not (Fig. 1). Even in the hepatobiliary phase
of Gd-EOB-DTPA-enhanced MRI, S8 tumor exhibited
an inhomogeneous image while S4 tumors exhibited a
well-demarcated low-density image (Fig. 2a). There were
no abnormal uptakes on FDG-PET in the liver (Fig. 2b).
As the patient had never pointed out the infection of
hepatitis virus and other liver pathogens, tumor markers
such as AFP and PIVKA-II were not measured. Our pre-
liminary diagnosis was that both tumors were liver me-
tastases of GIST. As increasing the dose of imatinib was
problematic because of the side effects in this patient, a
second hepatectomy was performed to remove these
two lesions (Fig. 3a). Histologically, the lesion in seg-
ment 4 was a liver metastasis of GIST with necrotic
changes, whereas the lesion in segment 8 was a primary
HCC (Fig. 3b). Follow-up for 12 months after the latest
surgery has shown no signs of recurrent disease.
Discussion
Distant metastases of GIST arise predominantly in the
liver and peritoneum. For example, of 80 patients with
primary GIST who underwent complete resection, 63 %
had recurrences in the liver, with the liver being the only
site of disease in 44 % of patients with recurrences. A
similar pattern was observed in 94 patients with metas-
tasis at presentation, in that 65 % had liver lesions and
53 % had isolated liver recurrence. Hepatic tumors
appearing after surgery for GIST should therefore be
regarded as liver metastases of GIST. Importantly, the
imaging findings of liver metastases of GIST vary and
can be altered by treatment with molecularly targeted
agents such as imatinib. Thus, subjective evaluations,
including changes in tumor nodules, density, and
vascularization, as well as changes in tumor size, are
optimal in evaluating therapeutic responses by CT [6].
Patients with GIST frequently experience synchronous
malignant tumors. For example, the frequency of malig-
nant neoplasms was significantly higher among patients
with GIST (22 %) than in the general population (4 %)
[7]. Carcinomas of the gastrointestinal tract are the most
frequent neoplasms associated with concomitant GIST,
with gastric and colorectal adenocarcinomas being most
prevalent [5]. Synchronous primary liver tumors have
been reported in few patients with GIST, including one
patient with a perivascular epithelioid cell tumor of the
liver [8] and three with HCC (one KIT-positive and two
KIT-negative) [9–11]. To our knowledge, this is the first
report of the co-occurrence of a liver metastasis of GIST
and a primary HCC in the liver.
The 5-year overall survival rate of isolated liver metas-
tasis of GIST with hepatectomy was reported as 50 %
[12], which was not poorer than that of early-stage HCC
[13]. However, the recurrence rate following surgical re-
section for hepatic metastases from GIST was reported
as high as 70–77 % [14]. Strict follow-up is needed in
such described case.
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Fig. 2 a Gd-EOB-DTPA-enhanced MRI appearance of two liver tumors,
in segments 4 and 8. b PET-CT appearance of two liver tumors,
in segments 4 and 8
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Conclusion
In conclusion, the co-occurrence of liver metastases of
GIST and primary HCC is extremely rare. Because of
differences in their treatment, synchronous hepatic le-
sions in patients diagnosed with GIST should be charac-
terized by obtaining independent biopsies. This may aid
in the correct and tailored treatment for individual
patients.
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Fig. 3 a Resected specimen containing the two liver tumors. b GIST with immunoexpression of KIT, hepatocellular carcinoma (H&E)
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